Flow Neuroscience

Executive Summary

Flow Neuroscience, founded in 2016 in Malmö, Sweden, is a digital health company developing a prescription home-use tDCS headset combined with a behavioral therapy app for treating depression. The device is CE-marked as a medical device and available directly to consumers in select markets, offering a non-invasive, medication-free alternative. The company operates in the growing field of neuromodulation and digital therapeutics, addressing a large global market of depression patients who are either treatment-resistant or seek non-pharmacological options. While the company has established a commercial footprint in Europe, its long-term growth hinges on expanding into the US market, building clinical evidence to support FDA clearance, and scaling production. The lack of disclosed funding and stage suggests the company may still be in early commercialization or bootstrapped, posing risks around financial sustainability and competitive pressure from other neuromodulation and digital health players.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for the US market40% success
• Q2 2026Publication of results from a pivotal clinical trial on tDCS for depression55% success
• Q3 2026Strategic partnership or distribution agreement with a major mental health provider50% success